Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial.

TL;DR

Adding all-trans retinoic acid (ATRA) to decitabine increased overall response rates from 51% to 78% in patients with myelodysplastic syndrome with excess blasts, and extended progression-free survival by 4.4 months . Overall survival improvement did not reach statistical significance.

What the Study Found

Myelodysplastic syndromes (MDS) with excess blasts represent a high-risk category where cancer cells accumulate in bone marrow but haven't yet progressed to acute myeloid leukemia. Standard treatment with decitabine, a hypomethylating agent, helps some patients but leaves many with poor outcomes. This multicenter randomized controlled trial tested whether combining ATRA, a differentiation-inducing drug, with decitabine could improve results compared to decitabine alone.

The study enrolled 227 patients (median age 62 years) across multiple centers and randomized them 1:1 to receive either ATRA at 25 mg/m2 daily plus decitabine at 20 mg/m2 on days 1-5, or decitabine monotherapy. The primary outcome measured within four treatment cycles was overall response rate, defined as complete remission, partial remission, or marrow complete remission. The ATRA combination group achieved a 78% response rate compared to 51% with decitabine alone, representing a statistically significant 27-percentage-point difference (odds ratio = 3.40; P < 0.001). Complete remission rates also favored the combination, at 23% versus 12% (P = 0.042). These response differences emerged quickly: investigators assessed outcomes within the first four cycles of therapy.

The survival benefit was more modest. With a median follow-up of 30.1 months, progression-free survival extended to 14.9 months in the ATRA group versus 10.5 months with decitabine alone, a 4.4-month difference that reached statistical significance (hazard ratio = 0.70; P = 0.03). However, overall survival showed a numerical but non-significant trend toward improvement: 23.0 months with ATRA plus decitabine versus 19.3 months with decitabine alone (hazard ratio = 0.77; P = 0.137). The confidence interval crossed 1.0, meaning the observed survival difference could plausibly be due to chance. Importantly, both groups experienced similar rates of grade 3 or higher blood cell toxicities, indicating the combination did not substantially increase hematological harm.

The magnitude of response rate improvement is clinically meaningful. In a disease where standard therapy produces less than 60% response rates, a nearly 30-point absolute increase addresses a clear unmet need. The progression-free survival benefit also matters: patients gained an additional year before their disease advanced. The non-significant overall survival difference suggests either that additional therapies given after progression offset the early advantage, or that the follow-up period wasn't long enough to capture the full benefit, or that early response doesn't fully predict long-term outcomes in this population.

What This Means for You

If you have MDS with excess blasts and are considering treatment options, this evidence supports discussion with your hematologist or oncologist about ATRA plus decitabine as a potential first-line approach. The substantially higher response rate means a greater likelihood of achieving disease control in the near term. The progression-free survival benefit translates to a meaningful delay before needing to consider alternative therapies.

The lack of increased hematological toxicity is reassuring, though any chemotherapy carries risks that require individualized assessment. Factors like age, organ function, and comorbidities influence tolerability and should guide treatment selection with your care team. This study involved adult patients with a median age of 62 years, so applicability to very elderly or very young patients may differ.

This research is specific to MDS with excess blasts and should not be interpreted as guidance for other MDS subtypes or other blood cancers. Treatment decisions in hematologic malignancies require specialist evaluation of your specific disease features, cytogenetics, and overall health status.

Study Details

Sources

Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial. Haematologica. PubMed ID: 41262042